4 "The results of ACHIEVE-3 highlight the potential advantages of orforglipron over oral semaglutide for type 2 diabetes: greater A1C reduction, more weight loss, and the ability to take it without food or water timing restrictions that's a combination that could matter significantly to people managing their disease day in and day out," said Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health
Read those week ranges loosely
The report concluded that those important data points were eliminated from the trials final analysis without reasonable explanation
This can lead to fewer cravings, smaller meal portions, less food noise or preoccupation with food in your head, better insulin sensitivity, and improved gut health
Sucher NJ, Lipton SA (1991)